Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY

v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY - USD ($)
$ in Thousands
Common stock
Additional paid in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total
Balance at the beginning of the period, shares at Dec. 31, 2022 987,109,890        
Balance at the beginning of the period at Dec. 31, 2022 $ 1,399 $ 990,656 $ (875) $ (909,302) $ 81,878
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 7 1     8
Issuance of shares upon exercise of stock options (in shares) 6,035,574        
Issuance of shares upon completion of public offering, net of issuance costs $ 1 187     188
Issuance of shares upon completion of public offering, net of issuance costs (in shares) 554,496        
Other comprehensive loss (gain)     (910)   (910)
Share-based compensation expense   1,676     1,676
Net profit/(loss)       1,036 1,036
Balance at the end of the period at Mar. 31, 2023 $ 1,407 992,520 (1,785) (908,266) 83,876
Balance at the end of the period, shares at Mar. 31, 2023 993,699,960        
Balance at the beginning of the period, shares at Dec. 31, 2022 987,109,890        
Balance at the beginning of the period at Dec. 31, 2022 $ 1,399 990,656 (875) (909,302) 81,878
Increase (Decrease) in Stockholders' Equity          
Net profit/(loss)         (20,353)
Balance at the end of the period at Jun. 30, 2023 $ 1,851 1,057,547 (3,092) (929,655) 126,651
Balance at the end of the period, shares at Jun. 30, 2023 1,351,828,044        
Balance at the beginning of the period, shares at Mar. 31, 2023 993,699,960        
Balance at the beginning of the period at Mar. 31, 2023 $ 1,407 992,520 (1,785) (908,266) 83,876
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 1 13     14
Issuance of shares upon exercise of stock options (in shares) 698,778        
Issuance of shares upon acquisition of TCR2 $ 443 60,320     60,763
Issuance of shares upon acquisition of TCR2 (in shares) 357,429,306        
Other comprehensive loss (gain)     (1,307)   (1,307)
Share-based compensation expense   4,694     4,694
Net profit/(loss)       (21,389) (21,389)
Balance at the end of the period at Jun. 30, 2023 $ 1,851 1,057,547 (3,092) (929,655) $ 126,651
Balance at the end of the period, shares at Jun. 30, 2023 1,351,828,044        
Balance at the beginning of the period, shares at Dec. 31, 2023 1,363,008,102       1,363,008,102
Balance at the beginning of the period at Dec. 31, 2023 $ 1,865 1,064,569 (3,748) (1,023,173) $ 39,513
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 8 66     74
Issuance of shares upon exercise of stock options (in shares) 6,297,720        
Issue of shares under At The Market sales agreement, net of commission and expenses $ 208 28,953     29,161
Issue of shares under At The Market sales agreement, net of commission and expenses (in shares) 163,669,056        
Other comprehensive loss (gain)     1,028   1,028
Share-based compensation expense   3,102     3,102
Net profit/(loss)       (48,503) (48,503)
Balance at the end of the period at Mar. 31, 2024 $ 2,081 1,096,690 (2,720) (1,071,676) $ 24,375
Balance at the end of the period, shares at Mar. 31, 2024 1,532,974,878        
Balance at the beginning of the period, shares at Dec. 31, 2023 1,363,008,102       1,363,008,102
Balance at the beginning of the period at Dec. 31, 2023 $ 1,865 1,064,569 (3,748) (1,023,173) $ 39,513
Increase (Decrease) in Stockholders' Equity          
Net profit/(loss)         21,018
Balance at the end of the period at Jun. 30, 2024 $ 2,083 1,099,758 (3,412) (1,002,155) $ 96,274
Balance at the end of the period, shares at Jun. 30, 2024 1,534,220,604       1,534,220,604
Balance at the beginning of the period, shares at Mar. 31, 2024 1,532,974,878        
Balance at the beginning of the period at Mar. 31, 2024 $ 2,081 1,096,690 (2,720) (1,071,676) $ 24,375
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 2       2
Issuance of shares upon exercise of stock options (in shares) 1,245,726        
Issue of shares under At The Market sales agreement, net of commission and expenses   10     10
Other comprehensive loss (gain)     (692)   (692)
Share-based compensation expense   3,058     3,058
Net profit/(loss)       69,521 69,521
Balance at the end of the period at Jun. 30, 2024 $ 2,083 $ 1,099,758 $ (3,412) $ (1,002,155) $ 96,274
Balance at the end of the period, shares at Jun. 30, 2024 1,534,220,604       1,534,220,604